Market Overview

Acer Therapeutics Shares Plunge On FDA Complete Response Letter

Share:
Acer Therapeutics Shares Plunge On FDA Complete Response Letter

Acer Therapeutics Inc (NASDAQ: ACER) shares were trading down more than 75% Tuesday after it received a letter from the Food and Drug Administration regarding its drug application for Edsivo in the treatment of vascular Ehlers-Danlos syndrome.

The FDA said it is necessary to conduct an adequate and well-controlled trial to determine whether celiprolol reduces the risk of clinical events in patients with vEDS.

The rare disorder is caused by a gene mutation affecting a major protein, which causes weakness in vessel walls and hollow organs.

Acer Therapeutics plans to request a meeting to discuss the FDA’s response.

“We remain committed to working closely with the FDA to fully understand its response,” CEO Chris Schelling said in a statement. “We expect to respond to the FDA in the third quarter of this year." 

Acer Therapeutics shares were down 77.36% at $4.36 at the time of publication. 

Related Links:

Genfit Partners With Terns Pharma To Develop, Commercialize Elafibranor In China

7 Stocks To Watch For June 25, 2019

Posted-In: Biotech News FDA Movers Trading Ideas General Best of Benzinga

 

Related Articles (ACER)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com